Entry Detail



General Information

Database ID:exR0089632
RNA Name:hsa-miR-22-3p
RNA Type:miRNA
Chromosome:chr17
Starnd:-
Coordinate:
Start Site(bp):1713914End Site(bp):1713935
External Links:hsa-miR-22-3p



Disease Information

Disease Name:Preterm Birth
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D047928
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Premature Birth//Birth, Premature//Births, Premature//Premature Births//Preterm Birth//Birth, Preterm//Births, Preterm//Preterm Births



Expression Detail

GEO ID:GSE106224
Description:Exosomal RNA may reflect placenta deficiencies and provide better biomarker in preterm birth
Experimental Design:Disease vs Control
Case Disease Type:Preterm Birth
Case Disease SubType:NA
Case Sample:Preterm Birth
Control Sample:Control
Number of Case:20
Number of Control:50
Number of Samples:70





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
CCDC97
chr19
41310172
41324873
+
AP1S1
chr7
101154456
101161596
+
RCOR1
chr14
102592649
102730561
+
RAB11FIP4
chr17
31391675
31538211
+
PPIF
chr10
79347469
79355334
+
FBXL19
chr16
30923055
30948783
+
FNBP4
chr11
47716494
47767443
-
DCP1A
chr3
53283429
53347586
-
GDAP1
chr8
74321130
74488872
+
WSB2
chr12
118032694
118062430
-
ITGA5
chr12
54395261
54419266
-
IRS2
chr13
109752695
109786583
-
FOXP1
chr3
70952817
71583993
-
TMEM179B
chr11
62787402
62790400
+
ETS1
chr11
128458761
128587558
-
ATP2C1
chr3
130850595
131016712
+
ZNF740
chr12
53180704
53195142
+
CACUL1
chr10
118674167
118755249
-
ATP6V0B
chr1
43974487
43978295
+
ACLY
chr17
41866917
41930542
-
CLASP1
chr2
121337776
121649587
-
PRLR
chr5
35048756
35230487
-
PDPR
chr16
70113626
70162537
+
WWC2
chr4
183099257
183320777
+
TAGLN
chr11
117199370
117207464
+
BCL9
chr1
147541501
147626216
+
GLIS2
chr16
4314761
4339597
+
GBF1
chr10
102245532
102382899
+
PDSS1
chr10
26697701
26746798
+
RANBP2
chr2
108719482
108785809
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001699
chr7
40027197
40041630
+
hsa_circ_0001414
chr4
56277780
56284152
+
hsa_circ_0000733
chr17
1561546
1562030
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC021078.1
chr5
149494314
149504670
-
AL360012.1
chr1
28648600
28648730
+
MALAT1
chr11
65497688
65506516
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
OIP5-AS1
chr15
41283990
41309737
+
SNHG16
chr17
76557764
76565348
+
Display:



Experiment Detail

GEO ID:GSE106224
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL18573
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:1522
Sample treatment protocol:Whole blood samples were centrifuged for 15 minutes at 2,000×g at 4°C to get plasma. EVs were isolated from 100 ul of plasma using size exclusion columns (iZON qEV, Cambridge MA) with de-gassed 1X PBS from a total of 22 selected samples, 11 from each group (Table 1). Eluate (~500 ul for each fraction) was collected in microfuge tubes individually. The protein contains and concentration for each fraction were assessed by protein gel electrophoresis and Bradford assay (BioRad, Hercules, CA).
RNA Extract protocol:RNA was isolated from all plasma samples, the 22 EV samples, and 22 corresponding EV-depleted fractions using miRNeasy Micro Kit (Qiagne, Germantown MD).
RNA library preparation protocol:Small RNA sequencing libraries were generated with a modified small RNAseq protocol (manuscript in preparation) that alleviates most of the adapter-miRNA ligation sequence bias problem.



Reference

PMID:29516617
Title:Extracellular vesicle RNAs reflect placenta dysfunction and are a biomarker source for preterm labour
Author:Fallen S, Baxter D, Wu X, Kim TK, Shynlova O, Lee MY, Scherler K, Lye S, Hood L, Wang K
Journal:J Cell Mol Med. 2018 May;22(5):2760-2773.
Description:We have used an improved small RNA library construction protocol and a newly developed size exclusion chromatography (SEC)-based EV purification method to gain a comprehensive view of circulating RNA in plasma and its distribution by analysing RNAs in whole plasma and EV-associated and EV-depleted plasma.